Detalles de la búsqueda
1.
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants.
Invest New Drugs
; 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38789848
2.
Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes.
Haematologica
; 108(4): 1196-1199, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36475522
3.
Mobocertinib: Mechanism of action, clinical, and translational science.
Clin Transl Sci
; 17(3): e13766, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38511563
4.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728048
5.
Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.
J Patient Rep Outcomes
; 5(1): 60, 2021 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-34283303
6.
Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care.
Leuk Lymphoma
; 60(1): 49-59, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29932781
7.
Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States.
Pharmacoecon Open
; 3(2): 237-245, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30324565
8.
A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent.
Leuk Res
; 78: 45-51, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30716655
9.
A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
J Patient Rep Outcomes
; 3(1): 35, 2019 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31218454
10.
Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Clin Lymphoma Myeloma Leuk
; 18(4): e157-e166, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29475821
11.
Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review.
Clin Lymphoma Myeloma Leuk
; 18(7): e303-e314, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29802009
12.
Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
Leuk Res
; 71: 27-33, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29944984
13.
Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
Oncogene
; 24(38): 5888-96, 2005 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15940263
14.
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
Clin Cancer Res
; 11(21): 7807-16, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16278403
15.
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Clin Cancer Res
; 11(21): 7825-33, 2005 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16278405
16.
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Cancer Res
; 62(3): 789-95, 2002 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-11830534
17.
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Leukemia
; 35(7): 2119-2124, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33483617
18.
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Leukemia
; 35(12): 3637, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34789825
19.
Pharmacokinetics and antitumor efficacy of XMT-1001, a novel, polymeric topoisomerase I inhibitor, in mice bearing HT-29 human colon carcinoma xenografts.
Clin Cancer Res
; 18(9): 2591-602, 2012 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22392910
20.
XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
Adv Drug Deliv Rev
; 61(13): 1193-202, 2009 Nov 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-19682517